

Celgene Corporation Investor Relations Department 86 Morris Avenue Summit, NJ 07901 United States

Visit IR website ☐ Sign-up for e-mail alerts ☐

NASDAQ: CELG	
Last Trade:	143.89
Trade Time:	4:00 PM ET Sep 22, 2017
Change:	0.11 <b>1</b> (0.077%)
Day Range	141.75 - 144.19
52-Week Range	96.93 - 144.59
Volume	3,549,466

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## **Company Profile**

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immuneinflammatory related diseases. Our portfolio of commercial products include REVLIMID®. VIDAZA<sup>®</sup>, THALOMID<sup>®</sup>, POMALYST®/IMNOVID®. ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... (more)

#### **Stock Performance**



## Press Releases [View all]

Sep 8, 2017

<u>Data Presented at ESMO 2017 Further</u> <u>Evaluate Role of ABRAXANE® for Patients</u> with Historically Challenging Cancers

Sep 7, 2017

<u>Celgene Provides Update on the Fusion™</u> <u>Clinical Program</u>

Aug 24, 2017

<u>Celgene Corporation to Webcast at Upcoming Investor Conferences</u>

Aug 1, 2017

FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation

Jul 28, 2017

<u>Celgene Corporation to Webcast at</u> Upcoming Investor Conference

#### Upcoming Events [View all]

Sep 26, 2017 9:45 AM ET

Cantor Fitzgerald 3rd Annual Healthcare

Conference

Events [View all]

# Financials [View all]

Feb 10, 2017 Annual Report (10-K)

Apr 27, 2017

Proxy Statement (DEF 14A)

Jul 27, 2017

Quarterly Report (10-Q)

Apr 27, 2017

Quarterly Report (10-Q)

Oct 27, 2016

Quarterly Report (10-Q)